Indivior Pharmaceuticals, Inc. (INDV)
35.06
+0.50
(+1.45%)
USD |
NASDAQ |
Sep 02, 16:00
35.06
0.00 (0.00%)
After-Hours: 16:04
Indivior Pharmaceuticals Research and Development Expense (TTM) : 53.00M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.00M |
| March 31, 2026 | 67.00M |
| December 31, 2025 | 80.00M |
| September 30, 2025 | 94.00M |
| June 30, 2025 | 96.00M |
| March 31, 2025 | 101.00M |
| December 31, 2024 | 107.00M |
| September 30, 2024 | 106.00M |
| June 30, 2024 | 102.00M |
| March 31, 2024 | 108.00M |
| December 31, 2023 | 107.00M |
| September 30, 2023 | 106.00M |
| June 30, 2023 | 108.00M |
| March 31, 2023 | 90.00M |
| December 31, 2022 | 71.00M |
| September 30, 2022 | 61.00M |
| June 30, 2022 | 52.00M |
| March 31, 2022 | 51.00M |
| December 31, 2021 | 52.00M |
| September 30, 2021 | 47.00M |
| June 30, 2021 | 44.00M |
| March 31, 2021 | 39.00M |
| Date | Value |
|---|---|
| December 31, 2020 | 40.00M |
| September 30, 2020 | 43.00M |
| June 30, 2020 | 46.00M |
| March 31, 2020 | 51.00M |
| December 31, 2019 | 53.00M |
| September 30, 2019 | 53.00M |
| June 30, 2019 | 58.00M |
| March 31, 2019 | 63.00M |
| December 31, 2018 | 67.00M |
| September 30, 2018 | 72.00M |
| June 30, 2018 | 79.00M |
| March 31, 2018 | 80.00M |
| December 31, 2017 | 89.00M |
| September 30, 2017 | 99.00M |
| June 30, 2017 | 105.00M |
| March 31, 2017 | 114.00M |
| December 31, 2016 | 120.00M |
| September 30, 2016 | 146.00M |
| June 30, 2016 | 153.00M |
| March 31, 2016 | 159.00M |
| December 31, 2015 | 148.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Supernus Pharmaceuticals, Inc. | 124.20M |
| Liquidia Corp. | 54.95M |
| Corcept Therapeutics, Inc. | 253.86M |
| Prestige Consumer Healthcare, Inc. | -- |
| Harrow, Inc. | 20.56M |